Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 626 - 650 of 13625 in total

Loracarbef

Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.
Approved
Investigational
Withdrawn
Matched Description: … Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …

Lomefloxacin

Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well.
Approved
Investigational
Matched Description: … Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. ... Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis …
Matched Categories: … Antibacterials for Systemic Use ... Antiinfectives for Systemic Use …

Isometheptene

Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches.
Approved
Matched Description: … It is used for treating migraines and tension headaches. ... Isometheptene is a sympathomimetic drug that causes vasoconstriction. …
Matched Categories: … Drugs for Functional Gastrointestinal Disorders …

Desipramine

Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive...
Approved
Investigational
Matched Description: … See toxicity section below for a complete listing of side effects. ... In depressed individuals, desipramine exerts a positive effect on mood. ... receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for …
Matched Categories: … Antidepressive Agents Indicated for Depression ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Lenograstim

Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent.
Approved
Investigational
Matched Description: … Lenograstim is a recombinant granulocyte colony-stimulating factor used as an immunostimulating agent …
Matched Products: … GRANOCYTE 34 FOR INJECTION 263 mcg/ml …

Plicamycin

Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
Approved
Investigational
Withdrawn
Matched Description: … The manufacturer discontinued plicamycin in 2000. ... It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Ceftobiprole

Ceftobiprole is a fifth-generation semisynthetic cephalosporin antibacterial which is available commercially as the prodrug ceftobiprole medocaril. Ceftobiprole is a broad-spectrum agent with demonstrated activity against both Gram-positive and Gram-negative bacteria, including antibiotic-resistant strains of Staphylcoccus aureus (methicillin-resistant Staphylococcus aureus; MRSA). The EMA's Committee for Medicinal Products for Human Use (CHMP)...
Approved
Investigational
Matched Description: … The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole ... [L50467] It received its first approval in Canada in October 2017 for use in certain patients with bacterial ... pneumonia,[L50472] and was subsequently approved in the United States with additional indications for …

Eflornithine

Eflornithine is an irreversible ornithine decarboxylase inhibitor originally developed as a treatment for human African trypanosomiasis. Further research has also implicated ornithine decarboxylase in other conditions like facial hirsutism and cancer, especially when ornithine decarboxylase is highly upregulated in tumor cells.[A4112, A262834] Additionally, ornithine decarboxylase is activated by c-myc or...
Approved
Withdrawn
Matched Description: … for human African trypanosomiasis. ... study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and a 68% ... for the treatment of African trypanosomiasis and hirsutism, respectively, but has since been discontinued …

Drotaverine

Drotaverine is an antispasmodic drug that works by inhibiting phosphodiesterase-4 (PDE4). It is a benzylisoquinoline derivative that is structurally related to papaverine, although it displays more potent antispasmodic activities than papaverine. Drotaverine has been used in the symptomatic treatment of various spastic conditions, such as gastrointestinal diseases, biliary dyskinesia, and...
Approved
Investigational
Matched Description: … It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689] ... [A231619] It is a benzylisoquinoline derivative that is structurally related to [papaverine], although ... [A7036] It also has been investigated in dysmenorrhea, abortion, [A231609] and augmentation of labour …
Matched Categories: … Drugs for Functional Gastrointestinal Disorders …

Pindolol

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s....
Approved
Investigational
Matched Description: … Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. ... [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s. …
Matched Categories: … Antihypertensive Agents Indicated for Hypertension …

Cinnamon oil

Approved
Experimental
Matched Products: … Nwk A-FV …

Flavin mononucleotide

A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. It is the principal form in which RIBOFLAVIN is found in cells and tissues.
Approved
Investigational
Matched Description: … A coenzyme for a number of oxidative enzymes including NADH DEHYDROGENASE. ... It is the principal form in which RIBOFLAVIN is found in cells and tissues. …
Matched Mixtures name: … Toni Com Liq ... Alsimine W Vitamins A D ... Tonicol Et A-D-C Ampoules/comprimes …

Lactitol

Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from lactose. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. sucrose). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides...
Approved
Investigational
Matched Description: … [A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in ... [A190918] It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet ... Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose …
Matched Categories: … Compounds used in a research, industrial, or household setting ... Drugs for Constipation …

Colchicine

Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Familial Mediterranean fever, and prevention of major cardiovascular events....
Approved
Matched Description: … Colchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as _Colchicum ... [A183611] Its use was first approved by the FDA in 1961. ... [L47591] It has also been investigated in other inflammatory and fibrotic conditions.[A183602] …
Matched Categories: … Experimental Unapproved Treatments for COVID-19 …

Daridorexant

Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Description: … Conventional treatments for insomnia include drugs targeting gamma-aminobutyric acid type-A (GABA-A), ... sleep and daytime functioning in patients with insomnia. ... Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat …

Phylloquinone

Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin.[L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates precursors to coagulation factors II, VII, IX, and X.[A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II,...
Approved
Investigational
Matched Description: … Vitamin K1, also called phylloquinone or phytonadione, is a fat soluble vitamin. ... [L33319,L33345] Phylloquinone is a cofactor of the enzyme γ-carboxylase, which modifies and activates ... [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation …
Matched Mixtures name: … Pediatric Infuvite Multiple Vitamins for Infusion …

Fruquintinib

Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and the VEGF/VEGFR pathway is one of the most critical pathways for this phenomenon.[A262102,A262107] Indeed, oncogenic activation,...
Approved
Investigational
Matched Description: … overall survival rate was observed in both trials. ... The first approach can be exemplified by [bevacizumab], a VEGF-A trap antibody. ... Therefore, the advent of fruquintinib, a new generation of VEGFR inhibitors with a high kinome selectivity …

Moxonidine

Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. As well, moxonidine has been shown...
Approved
Investigational
Matched Description: … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild ... It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors …

Human calcitonin

Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering effect. It is constituted as a 32-amino acid single chain polypeptide structure that gets secreted as a regulatory agent in calcium-phosphorus metabolism. It is used as an alternative for people developing antibodies against salmon calcitonin.
Approved
Investigational
Matched Description: … a regulatory agent in calcium-phosphorus metabolism. ... Calcitonin was first discovered in isolated parathyroid tissue as a substance with a serum-calcium-lowering ... [A32098] It is used as an alternative for people developing antibodies against salmon calcitonin. …

Aceclofenac

Aceclofenac is an oral non-steroidal anti-inflammatory drug (NSAID) with marked anti-inflammatory and analgesic properties used to treat osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670]. Aceclofenac potently inhibits the...
Approved
Investigational
Matched Description: … It is a more commonly prescribed drug in Europe. ... In 1991, aceclofenac was developed as an analog of a commonly prescribed NSAID, [DB00586], via chemical ... It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional …
Matched Categories: … Topical Products for Joint and Muscular Pain ... Antiinflammatory Preparations, Non-Steroids for Topical Use …

Erlotinib

Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)...
Approved
Investigational
Matched Description: … Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion ... form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion ... Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …

Tepotinib

Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell...
Approved
Investigational
Matched Description: … In February 2022, tepotinib was approved for use in Europe.[L42200] ... [A228058] MET is a desirable target in the treatment of certain solid tumors as it appears to play a ... Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers …

Tildrakizumab

Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy in ... promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255]. ... The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults …

Motixafortide

Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection prior to autologous transplantation. Hematopoietic stem cell transplantation (HSCT) is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's...
Approved
Investigational
Matched Description: … , for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple ... Motixafortide is a cyclic peptide hematopoietic stem cell mobilizer used to improve stem cell collection ... of C-X-C Motif Chemokine Receptor 4 (CXCR4), a protein that helps to anchor stem cells to bone marrow …

Maralixibat

Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like odevixibat.[A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome. Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, rifampin, ursodeoxycholic acid, cholestyramine, naltrexone, and...
Approved
Investigational
Matched Description: … [L38834] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended ... pruritus and treatments were given based on a prescriber's clinical experience. ... [A236823,A239249,L38834] Maralixibat is indicated for the treatment of cholestatic pruritus in patients …
Displaying drugs 626 - 650 of 13625 in total